تـأثير العلاج بالمتفورمين على حالة مقاومة الانسولين في النساء المصابات بمرض تكيس المبايض

[1]- Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, & Azziz R. Prevalence of the Polycystic Ovary Syndrome in unselected black and white Women of the Southeastern United States: A prospective study 1. The Journal of Clinical Endocrinology & Metabolism 1998; 83: 3078-3082.

[2]- Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, & Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected

population. J Clin Endocrinol Metab 2004; 89: 2745-2749.

[3]- Franks S. Polycystic ovary syndrome. N Engl J Med 1995; 333: 853-861.

[4]- Kyei-Mensah A, Maconochie N, Zaidi J, Pittrof R, Campbell S, & Tan SL (1996). Transvaginal three-dimensional ultrasound: reproducibility of ovarian and endometrial volume measurements. Fertility and sterility 1996; 66: 718-722.

[5]- Chang RJ, Nakamura RM, Judd HL, & Kaplan SA. Insulin resistance in non obese patients with polycystic ovary disease. The endocrine Society 1983; 57: 356-359.

[6]- Dunaif A, Segal KR, & Futterweit W. Profound peripheral insulin resistance independent of obesity in polycystic ovary syndrome. Diabetes 1989; 38: 1165-1174.

[7]- Osei K & Schuster DP. Ethnic differences in secretion, sensitivity, and hepatic extraction of insulin in black and white Americans. Diabetic medicine 1994;11: 755-762.

[8]- Toprak S, Yonem A, çakir B, Guler S, Azal o, Ozata M, & çorakci A. Insulin resistance in nonobese patients with polycystic ovary syndrome. Hormone Research in Paediatrics 2001; 55: 65-70.

[9]- Legro RS, Kunselman A, Dodson WC, & Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 1999;84: 165-169.

[10]- Welt CK, Arason G, Gudmundsson JA, Adams J, Palsdottir H, Gudlaugsdottir G, Ingadottir G, & Crowley WF. Defining constant versus variable phenotypic features of women with polycystic ovary syndrome using different ethnic groups and populations. The Journal of Clinical Endocrinology & Metabolism 2006; 91: 4361-4368.

[11]- Poretsky L, Cataldo NA, Rosenwaks Z, & Giudice LC. The insulin-related ovarian regulatory system in health and disease. Endocrine reviews 1999; 20: 535-582.

[12]- Dunaif A. Insulin resistance in women with polycystic ovary syndrome. Fertil Steril 2006; 86: Suppl 1, S13-S14.

[13]- Ehrmann DA, Liljenquist DR, Kasza K, Azziz R, Legro RS, & Ghazzi MN. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. The Journal of Clinical Endocrinology & Metabolism 2006; 91: 48-53.

[14]- Franks S, Webber LJ, Goh M, Valentine A, Whit DM, Conway GS, Wiltshire S, & McCarthy MI. Ovarian morphology is a marker of heritable biochemical traits in sisters with polycystic ovaries. J Clin Endocrinol Metab 2008; 93: 3396-3402.

[15]- Norman RJ, Masters S, & Hague W. Hyperinsulinemia is common in family members of women with polycystic ovary syndrome. Fertility and sterility 1996; 66, 942-947.

[16]- Nestler JE, Jakubowicz DJ, Evans WS, & Pasquali R. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. New England Journal of Medicine 1998; 338: 1876-1880.

[17]- Kolodziejczyk B, Duleba AJ, Spaczynski RZ, & Pawelczyk L. Metformin therapy decreases hyperandrogenism and hyperinsulinemia in women with polycystic ovary syndrome. Fertility and sterility 2000; 73: 1149-1154.

[18]- Nawrocka J & Starczewski A. Effects of metformin treatment in women with polycystic ovary syndrome depends on insulin resistance. Gynecological Endocrinology 2007; 23: 231-237.

[19]- Velazquez EM, Mendoza S, Hamer T, Sosa F, & Glueck CJ. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism 1994; 43: 647-654.

[20]- Gupta S, Chen D, O.G. Brien KO, Chandra A, Metterle L, Kesavan S, & Agarwal A. Adolescent polycystic ovary syndrome: pathophysiology and implications of the disease. Arch MedSci 2009; 5: S115-S131.

[21]- Gupta MM, Chari S, Chandankhede M, & Ghike S. Insulin Resistance and Homocysteine Levels in Patients with Polycystic Ovarian Syndrome. Journal of South Asian Federation of Obstetrics and Gynaecology 2013; 5: 49-51.

[22]- Agarwal N, Gangopadhyay S, Koch N, Gupta A, Batra A, & Kabi BC. Polycystic ovarian syndrome and insulin resistance: a North Indian study. International Journal of Research in Medical Sciences 2015; 5 Jun;3(6):1321-1324

[23]- Huang J, Ni R, Chen X, Huang L, Mo Y, & Yang D. Metabolic abnormalities in adolescents with polycystic ovary syndrome in south China. Reproductive Biology and Endocrinology 2010; 8: 1.

[24]- Holte J, Bergh T, Berne C, Wide L, & Lithell H. Restored insulin sensitivity but persistently increased early insulin secretion after weight loss in obese women with polycystic ovary syndrome. The Journal of Clinical Endocrinology & Metabolism 1995; 80: 2586-2593.

[25]- Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997; 18: 774-800.

[26]- Esfahanian F, Zamani MM, & Heshmat R. Effect of Metformin compared with hypocaloric diet on serum C_reactive protein level and insulin resistance in obese and overweight women with polycystic ovary syndrome. Journal of Obstetrics and Gynaecology Research 2013; 39: 806-813.

[27]- Nawrocka-Rutkowska J, Ciecwiez S, Marciniak A, Brodowska A, Wisniewska B,

Kotlega D, & Starczewski A. Insulin resistance assessment in patients with polycystic ovary syndrome using different diagnostic criteriaG_ôImpact of metformin treatment. Annals of Agricultural and Environmental Medicine 2013; 20.

[28]- Tang T, Lord JM, Norman RJ, Yasmin E, & Balen AH. Insulin - sensitising drugs (metformin, rosiglitazone, pioglitazone, Dchiro inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. The Cochrane Library Cochrane Database Syst Rev. 2012; May 16;(5),DOI 10.1002

[29]- Diamanti-Kandarakis E, Kouli C, Tsianateli T, & Bergiele A. Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome. European Journal of Endocrinology 1989; 138: 269-274.

[30]- Eshre TT & Group A-SPCW (2008). Consensus on infertility treatment related to polycystic ovary syndrome. Fertility and sterility 2008; 89: 505-522.